Evaluation of Auto Antibodies in Oral Sub Mucous Fibrosis
1 other identifier
observational
70
1 country
1
Brief Summary
The etiology of OSMF is considered to be multifactorial. However, Role of autoimmunity had been suggested as one of the factors but remains unproven. The present study is undertaken to evaluate the presence of auto antibodies in OSMF patients to pave a way for new arena of treatment with the etiology of this persistent condition
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for all trials
Started Jan 2015
Typical duration for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
January 1, 2015
CompletedFirst Submitted
Initial submission to the registry
November 7, 2016
CompletedFirst Posted
Study publicly available on registry
January 5, 2017
CompletedPrimary Completion
Last participant's last visit for primary outcome
November 1, 2017
CompletedStudy Completion
Last participant's last visit for all outcomes
December 1, 2017
CompletedDecember 19, 2017
December 1, 2017
2.8 years
November 7, 2016
December 18, 2017
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Evaluation of auto antibodies in oral sub mucous fibrosis
The subjects in the study suffering from oral submucous fibrosis will be clinically evaluated and graded based on criteria given by Khanna et al classification. All the subjects included in the study will also be subjected to serum analysis for presence of auto antibodies in their serum by Titerplane technique.
one and half year
Study Arms (2)
oral sub mucous fibrosis
patients suffering with oral sub mucous fibrosis due to gutka/pan chewing confirmed by clinical examination
control group
patients having gutka/ pan chewing habit without oral sub mucous fibrosis in oral cavity
Eligibility Criteria
A total number of patients were 70 patients (Group A- 35 OSMF patients, Group B- 35 controls) of both the genders
You may qualify if:
- Patients who are willing for the study.
- A positive history of chewing arecanut, and/or smoking tobacco and alcohol.
- Patients with clinical and histopathological features of oral submucous fibrosis.
- Patients with OSMF not under any treatment for the same
You may not qualify if:
- Unwilling patients who do not want to be part of the study.
- Patients with known autoimmune disorders.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Panineeya Institute of Dental Sciences
Hyderabad, Telangana, 500060, India
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
NALLAN CHAITANYA, MDS
ASSOCIATE PROFESSOR
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- ASSOCIATE PROFESSOR, DEPARTMENT OF ORAL MEDICINE AND RADIOLOGY
Study Record Dates
First Submitted
November 7, 2016
First Posted
January 5, 2017
Study Start
January 1, 2015
Primary Completion
November 1, 2017
Study Completion
December 1, 2017
Last Updated
December 19, 2017
Record last verified: 2017-12
Data Sharing
- IPD Sharing
- Will not share